2017 Keynote Speakers:
- Mar. 1983 - Graduated from Kumamoto prefectural Kumamoto Technical High School
- Aug. 2016 - Parliamentary Vice-Minister of Health, Labour and Welfare (Reshuffled Third Abe Cabinet)
- Jan. 2016 - Director, Committee on Rules and Administration, House of Councillors (HC)
- Nov. 2015 - Deputy Chairman, Diet Affair Committee, Liberal Democratic Party (LDP); Deputy Director, Fisheries Division, LDP; Deputy Director, Local Organization and Local Assembly Member Division
- Jul. 2015 - Director, Special Committee on Legislation for Peace and Security of Our Nation and International Community, HC
- Oct. 2014 - Director, Committee on Budget, HC
- Sept. 2014 - Deputy Director, Agriculture and Forestry Division, LDP
- Nov. 2013 - Deputy Chairman, Committee on Organizations Involved with Agriculture, Forestry, and Fisheries, Party and Campaign Headquarters, LDP
- Oct. 2013 - Member, Committee on Audit, HC; Member, Special Committee on Disasters, HC
- Aug. 2013 - Member, Committee on Agriculture, Forestry, and Fisheries, HC
- Jul. 2013 - Elected to the HC in the 23 rd General Election
- Jun. 2011 - Deputy Chairman, National Association of Chairpersons of Prefectural Assemblies
- May 2011 - President, Kumamoto Prefectural Assembly
- May 2007 - Vice-President, Kumamoto Prefectural Assembly
- Dec. 1997 - Re-elected to the Kumamoto Prefectural Assembly for the fifth consecutive term
- Apr. 1991 - Elected to the Kumamoto Prefectural Assembly for the second consecutive term
Philippe Fauchet joined GlaxoSmithKline K.K. as President & Representative Director in January 2010. He is a member of the Pharmaceutical Operations Committee of GSK Plc. Philippe joined the company from Sanofi-aventis where he was President & Representative Director of sanofi-aventis Japan from 2005-2008 before being appointed Senior Vice President, Corporate Business Development Head of sanofi-aventis Group in January 2009. He served as a member of the Management Committee of sanofi-aventis Group from 2005. Philippe started his career in the pharmaceutical industry in 1984 at Hoechst Marion Roussel where he occupied, among others, various positions related to the Asia Pacific including positions in Japan and Korea from 1989-1994. He joined Sanofi-Synthelabo in 1996 and held regional positions before serving as President & Representative Director of Sanofi-Synthelabo K.K. from 2001-2004, then of sanofi-aventis K.K. until 2008. Philippe is Vice Chairman of the European Federation of Pharmaceutical Industries and Associations (EFPIA) Japan, a position he took up on 1 January 2014 after completing his two-year term as Chairman. He was also elected to the board of the British Chamber of Commerce in Japan (BCCJ) in April 2015, and re-elected in April 2016 and appointed French Foreign Trade Advisor (CCE) on recommendation of the Minister for Foreign Trade. Philippe is also a Board Member of JCR Pharmaceuticals Co., Ltd (4552.T) and of Japan Vaccine Co., Ltd, a joint venture between GSK and Daiichi Sankyo. He was awarded Honorary Officer of the Most Excellent Order of the British Empire (OBE) by the Queen in October 2014 and was recognized at an investiture ceremony in June 2015.
David Meeker is Executive Vice President and Head of Sanofi Genzyme, the specialty care global business unit of Sanofi which focuses on rare diseases, multiple sclerosis, oncology, and immunology. As an Executive Vice President of Sanofi, he is a member of the Executive Committee. Dr. Meeker joined Genzyme in 1994 as Medical Director to work on the Cystic Fibrosis Gene Therapy program. Subsequently, as Vice President, Medical Affairs, he was responsible for the development of rare disease therapies that today represent transformative and life-saving advancements in medicine for patients. Prior to the merger with Sanofi in 2011, Dr. Meeker was Chief Operating Officer, responsible for Genzyme’s commercial organization, overseeing its business units¸ country management organization and global market access functions. In October 2011 he was appointed President and Chief Executive Officer of Genzyme, a Sanofi company. Prior to joining Genzyme, Dr. Meeker was the Director of the Pulmonary Critical Care Fellowship at the Cleveland Clinic and an assistant professor of medicine at Ohio State University. He has authored more than 40 articles and multiple book chapters. Dr. Meeker received his MD from the University of Vermont Medical School. He completed the Advanced Management Program at Harvard Business School in 2000.
Dr. Jingsong Wang is the CEO of Harbour Biomed (HBM). Before founding HBM, he was the Head of China Research and Development and of Translational Medicine, Asia Pacific, for Sanofi. Dr. Wang joined Sanofi from Bristol-Myers Squibb, where he served in multiple roles with increasing responsibilities, including Director of Discovery Medicine and Clinical Pharmacology and Global Program Lead for multiple pre-clinical and clinical assets. Dr. Wang completed his Clinical Rheumatology Fellowship and subsequently was an Attending Rheumatologist and faculty member at Brigham and Women's Hospital and Harvard Medical School. Dr. Wang received his PhD in Molecular Pharmacology from China Pharmaceutical University and has also completed a Molecular Immunology Research Fellowship at Dr. Laurie Glimcher’s laboratory at the Harvard School of Public Health. Dr. Wang is an Adjunct Assistant Professor of Medicine at the University of Pennsylvania. He has served on the Research Grant Review Committee, National Natural Science Foundation of China, and as a scientific grant reviewer for the Medical Research Council, National Institute for Health Research, National Health Service of the United Kingdom.
Subesh Williams is Senior Vice President, Global Corporate Development at GSK plc. Subesh is responsible for M&A and Business Development across GSK’s commercial pharmaceuticals, Consumer Healthcare and Vaccines businesses. Subesh has over seven years of experience in M&A and has been involved in executing a number of transactions, including the creation of ViiV Healthcare (a HIV JV with Pfizer and Shionogi), the 3- part deal with Novartis which involved the acquisition of Novartis’ vaccines business, the creation of a JV in Consumer Healthcare and the sale of GSK’s oncology business, the creation of a JV with Verily in bioelectronics as well as a number of other acquisitions and divestments.Subesh has a number of years of pharmaceutical experience in various roles within Finance and Corporate Development.Prior to taking on this role, Subesh was CFO of ViiVHealthcare, a joint venture between GSK , Pfizer and Shionogi. Subesh is a chartered accountant and, prior to joining GSK, was a manager at PwC.
Tuesday, March 14, 2017
|8:00 - 8:55||Networking Breakfast|
|8:00 - 8:55||BIO One-on-One Partnering™ Meetings|
|9:00 - 9:20||Welcome Remarks|
|9:20 - 9:55||Opening Plenary: Seishi Baba, Parliamentary Vice-Minister of Health, Labour and Welfare|
|10:00 - 11:55||BIO One-on-One Partnering™ Meetings|
|10:00 - 11:55||Company Presentations|
|10:15 - 11:00||Keynote Session:
David Meeker, MD, Executive Vice President, Sanofi and Head, Genzyme Sanofi
|11:00 - 11:45||Addressing Shifts in Japanese Reimbursement Policy|
|12:00 - 13:25||Luncheon Plenary - Fireside Chat:|
|13:30 - 17:55||BIO One-on-One Partnering™ Meetings|
|13: 45 - 17:00||Company Presentations|
|14:00 - 14:55||Fighting Neurodegeneration: New Models for Alzheimer’s Disease and Beyond|
|15:00 - 15:55||Market Outlook— The Rise of Cross-Asia Partnerships|
|16:00 - 16:55||Update: Cancelled Session Expanding the Venture Capital Community in Asia|
|18:00 - 19:30||Welcome Reception
Roppongi Hills Club
Wednesday, March 15, 2017
|8:00 - 8:55||Networking Breakfast|
|8:00 - 11:55||BIO One-on-One Partnering™ Meetings|
|8:00 - 11:55||Company Presentations|
|9:00 - 9:45||Economic and Patient Impact of the Biomedical Research Community in Japan|
|9:45 - 10:30||Seeing Connections: Common Industry Growth Priorities for the Pacific Rim|
|10:45 - 11:40||Finding Cross-Border Clinical Trial Partners to Accelerate Approvals|
|12:00 - 13:25||Luncheon Plenary - Fireside Chat:
Jingsong Wang, MD, PhD, Chief Executive Officer, Harbour BioMed
|13:45 -14:40||Growing Translational Research Across Asia|
|13:30 - 17:55||BIO One-on-One Partnering™ Meetings|
|13:45 - 15:30||Company Presentations|
*as of 3/2/2017 - Subject to change
- Joseph Damond, Senior Vice President, International Affairs, Biotechnology Innovation Organization (BIO)
- Tim Earle, Chief Operating Officer and Chief Business Officer, TauRx Pharmaceuticals Ltd
- Carl Firth, PhD, Founder and Chief Executive Officer, Aslan Pharmaceuticals Pte. Ltd.
- David Flores, President and Chief Executive Officer, BioCentury Inc.
- Kyle Hathaway, PhD, Director of Policy and Government Relations, Asia Pacific, MSD
- Kei Katsuno, MD, MPH, Director, Investment Strategy and Development, Global Health Innovative Technology (GHIT) Fund
- Benjamin Li, PhD, Chief Executive Officer, Lee's Pharmaceutical Holdings Ltd.
- Bo Liu, PhD, Principal, Venture Investments, Johnson & Johnson Innovation – JJDC, Inc.
- Ellen Lubman, Vice President, External Science & Innovation, Allergan PLC
- Kevin J. Lynch, PhD, Vice President, Search and Evaluation, AbbVie
- Christopher U. Missling, PhD, President and Chief Executive Officer, Anavex Life Sciences Corp.
- Yoko Nakata, Public & Industry Policy, Health Policy, MSD K.K.
- Naomi Sakurai, President and Representative Director, Cancer Solutions Co., Ltd. (CANSOL)
- Charles Stacey, MD, Chief Executive Officer, Accera
- Yasuhiro Suzuki, MD, PhD, Director General of the Health Insurance Bureau, Ministry of Health, Labour and Welfare (MHLW), Japan
- Yoshiaki Tsukamoto, Executive Director, Japan Bioindustry Association (JBA)
- John Winebarger, President and Chief Executive Officer, Integrated Development Associates Co., Ltd.
- Tatsumi Yamazaki, PhD, Chairman of the Steering Committee, Japan Bioindustry Association (JBA)
- Jin-San Yoo, PhD, President and Chief Executive Officer, PharmAbcine Inc.
- Zhenping Zhu, MD, PhD, President of R&D and Chief Scientific Officer, 3SBio Inc.
*speakers added daily
Recently announced plans in Japan to reconfigure reimbursement policies for medicines combine with a worldwide discussion on the sustainability of traditional approaches to paying for healthcare. This session will dive deeply on the policy shifts underway in Japan and place them in context with policy shifts globally, while providing concrete advice on steps innovative drug companies should take to communicate the value they offer to patients.
More than 200 companies and more than 100 academic institutions, employing thousands of researchers and other staff, are deeply involved in innovating the next generation of medicines that Japan will be able to use to treat the ailments of its own citizens and export to help improve lives worldwide. This session will hear researchers and their supporters describe how the biomedical research community can most effectively contribute to the success of the Japan Ministry of Health, Labour and Welfare’s proposed Health Care 2035 initiative.
After years of attempts to cultivate a “Silicon Valley” mindset for the biotech industry outside the United States, recent bursts of investment activity from funds in Hong Kong, Singapore, and elsewhere in Asia, suggest the notion is gaining traction. These funds are reinventing how Asian biotech firms can get funding and investors will share what they look for when selecting portfolio companies. This session will also examine how the most active, private biotech funds already based in Asia built their momentum and how a robust venture capital community might be fostered throughout the region, including corporate venture capital perspectives too.
With more than 5 million people already suffering from neurodegenerative diseases in Japan, a number expected to rise nearly 50% in the next decade as the population ages, the challenge of finding treatments grows even more critical. Years of clinical trial disappointments have inspired a diversification in the selection of biological mechanisms to attack with new treatment approaches. This session will feature several companies exploring innovative therapeutic angles on treating Alzheimer’s disease and other neurodegenerative diseases.
While each national market regulator has individualized expectations regarding clinical trial design, efforts at normalization have made it increasingly possible to achieve cost savings by pursuing multinational trials. Recognizing the significant investments and patient recruitment challenges for testing new drugs, some medical centers and even cities, such as Seoul, are proactively making conducting trials easier for foreign firms. This panel will feature experts in identifying trial partners and choosing sites for trials in Asia.
High quality research continues to grow in Japan, China and South Korea, but the ability to commercialize homegrown discoveries has not been keeping pace. The three nations have profound differences in approaches to intellectual property, entrepreneurship, and the role of local government in promoting the growth of a biotech ecosystem. This panel will discuss those differences and consider whether there are common strategies to boost translational research programs across the region.
As biotech grows in Asia, innovators are increasingly looking for cross-Asia partnerships to access capital, talent and clinical trial sites to speed product development. In South Korea, several innovators have out-licensed local rights to emerging China players. At the same time, innovators elsewhere in Asia have partnered with South Korean firms to accelerate development of their own pipelines. This panel will examine several significant cross-Asia deals to identify lessons learned for Asia dealmakers.
Although regulatory environments differ and there are significant variations in research funding traditions, the biomedical leading nations of the Pacific Rim have major commonalities in priorities for supporting the growth of biotechnology companies and therapeutic pipelines. Hear from senior members of the biotech trade associations of Japan, Korea, Taiwan, and the United States, about ways to support and learn from one another’s successes, especially after set-backs in the Trans-Pacific Partnership.